Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer

Area of Science:

• Gynecologic Oncology
• Surgical Oncology
• Clinical Trials

Background:

• Limited data exist on survival outcomes comparing sentinel-lymph-node biopsy alone versus lymphadenectomy in cervical cancer.
• Evaluating alternative surgical approaches is crucial for optimizing patient care.

Purpose of the Study:

• To compare disease-free survival and complication rates between sentinel-lymph-node biopsy alone and pelvic lymphadenectomy in early-stage cervical cancer patients.
• To determine if sentinel-lymph-node biopsy alone is noninferior to lymphadenectomy.

Main Methods:

• A multicenter, randomized, noninferiority trial involving 838 patients with early-stage cervical cancer (IA1-IIA1).
• Patients were assigned to either sentinel-lymph-node biopsy alone or pelvic lymphadenectomy.
• Primary endpoint was 3-year disease-free survival; secondary endpoints included recurrence and complications.

Main Results:

• 3-year disease-free survival was 96.9% for biopsy-only versus 94.6% for lymphadenectomy (noninferior).
• The biopsy-only group had significantly lower rates of lymphocyst, lymphedema, paresthesia, and pain.
• No retroperitoneal nodal recurrences were observed in the biopsy-only group.

Conclusions:

• Sentinel-lymph-node biopsy alone is a safe and effective alternative to lymphadenectomy for early-stage cervical cancer.
• This approach achieves comparable disease-free survival with a reduced complication profile.
• The findings support the adoption of sentinel-lymph-node biopsy alone in clinical practice.